{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:42:10Z","timestamp":1792057330863,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Millennium Pharmaceuticals,\u00a0Inc."},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010293","name":"Seattle Genetics, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ADCT\u00a0Therapeutics"},{"name":"Aileron"},{"name":"Forty-Seven"},{"name":"Infinity"},{"name":"Verastem"},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014491","name":"Pharmacyclics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016253","name":"ATARA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016253","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Trillium Therapeutics"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GSK"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dhome","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Horizon"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ejca.2020.04.010","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T23:43:35Z","timestamp":1591055015000},"page":"120-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Patient-reported quality of life in patients with relapsed\/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study"],"prefix":"10.1016","volume":"133","author":[{"given":"Reinhard","family":"Dummer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry M.","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Scarisbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Wolter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Eradat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Pinter-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Sanches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo L.","family":"Ortiz-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg E.","family":"Akilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7348-2571","authenticated-orcid":false,"given":"Larisa","family":"Geskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auris","family":"Huen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Walewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2454-2800","authenticated-orcid":false,"given":"Julie","family":"Lisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshara","family":"Richhariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Feliciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4903-2762","authenticated-orcid":false,"given":"Erin","family":"Zagadailov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul R.","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.04.010_bib1","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8829.1","article-title":"An overview of cutaneous T cell lymphomas","volume":"5","author":"Bagherani","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.ejca.2020.04.010_bib2","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/exd.13701","article-title":"Molecular pathogenesis of cutaneous lymphomas","volume":"27","author":"Stadler","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.ejca.2020.04.010_bib3","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/cam4.472","article-title":"Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries","volume":"4","author":"Litvinov","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2020.04.010_bib4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.04.010_bib5","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","article-title":"EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma","volume":"118","author":"Kempf","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.04.010_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/sezary syndrome \u2013 update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2020.04.010_bib7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.04.010_bib8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jpainsymman.2012.01.012","article-title":"Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma","volume":"45","author":"Wright","year":"2013","journal-title":"J Pain Symptom Manag"},{"key":"10.1016\/j.ejca.2020.04.010_bib9","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/cncr.22252","article-title":"Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey","volume":"107","author":"Demierre","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2020.04.010_bib10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/bjd.13849","article-title":"Management of advanced cutaneous T-cell lymphoma: role of the dermatologist in the multidisciplinary team","volume":"173","author":"Poligone","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.04.010_bib11","series-title":"ADCETRIS\u00ae (brentuximab vedotin) summary of product characteristics","author":"European Medicines Agency","year":"2018"},{"key":"10.1016\/j.ejca.2020.04.010_bib12","series-title":"For injection, for intravenous use [Prescribing information]","author":"ADCETRIS\u00ae (brentuximab vedotin)","year":"2019"},{"key":"10.1016\/j.ejca.2020.04.010_bib13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.04.010_bib14","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archderm.1997.03890470111018","article-title":"Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases","volume":"133","author":"Chren","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2020.04.010_bib15","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2133.2008.08992.x","article-title":"Quality of life and psychological distress in patients with cutaneous lymphoma","volume":"160","author":"Sampogna","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.04.010_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.141.3.325","article-title":"Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma","volume":"141","author":"Demierre","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2020.04.010_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/A:1015276414526","article-title":"Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening","volume":"11","author":"Cella","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2020.04.010_bib18","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s11136-004-7713-0","article-title":"Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D","volume":"14","author":"Walters","year":"2005","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2020.04.010_bib19","series-title":"Handbook of disease burdens and quality of life measures","first-page":"87","article-title":"The EQ-5D health-related quality of life questionnaire","author":"Gusi","year":"2010"},{"key":"10.1016\/j.ejca.2020.04.010_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jclinepi.2009.01.024","article-title":"The minimal detectable change cannot reliably replace the minimal important difference","volume":"63","author":"Turner","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2020.04.010_bib21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2020.04.010_bib22","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1365-4632.2011.05188.x","article-title":"Prevalence and severity of pruritus in cutaneous T cell lymphoma","volume":"51","author":"Vij","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ejca.2020.04.010_bib23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bjd.13732","article-title":"\u2018We had to change to single beds because I itch in the night\u2019: a qualitative study of the experiences, attitudes and approaches to coping of patients with cutaneous T-cell lymphoma","volume":"173","author":"Beynon","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.04.010_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaad.2009.12.056","article-title":"The spectrum of hair loss in patients with mycosis fungoides and Sezary syndrome","volume":"64","author":"Bi","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.04.010_bib25","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s11136-016-1278-6","article-title":"The use and impact of quality of life assessment tools in clinical care settings for cancer patients, with a particular emphasis on brain cancer: insights from a systematic review and stakeholder consultations","volume":"25","author":"King","year":"2016","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2020.04.010_bib26","doi-asserted-by":"crossref","first-page":"E70","DOI":"10.1188\/12.ONF.E70-E83","article-title":"Physician, patient and contextual factors affecting treatment decisions in older adults with cancer: a literature review","volume":"39","author":"Tariman","year":"2012","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.ejca.2020.04.010_bib27","series-title":"Guideline on evaluation of anticancer medicinal products in man","year":"2017"},{"key":"10.1016\/j.ejca.2020.04.010_bib28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-4-70","article-title":"Responsiveness and minimal important differences for patient reported outcomes","volume":"4","author":"Revicki","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ejca.2020.04.010_bib29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13075-015-0658-6","article-title":"Approaches for estimating minimal clinically important differences in systemic lupus erythematosus","volume":"17","author":"Rai","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ejca.2020.04.010_bib30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.2017.35.5_suppl.120","article-title":"Brentuximab-induced peripheral neuropathy: risk factors and patient experiences","volume":"35","author":"Nagle","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.010_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/1078-0432.CCR-12-0290","article-title":"Brentuximab vedotin","volume":"19","author":"Deng","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2020.04.010_bib32","series-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims","author":"US Food and Drug Administration","year":"2009"},{"key":"10.1016\/j.ejca.2020.04.010_bib33","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/jamaoncol.2016.3328","article-title":"Trustworthiness of patient-reported outcomes in unblinded cancer clinical trials","volume":"3","author":"Atkinson","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.04.010_bib34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M15-0288","article-title":"Good publication practice for communicating company-sponsored medical research: GPP3","volume":"163","author":"Battisti","year":"2015","journal-title":"Ann Intern Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:27:08Z","timestamp":1760732828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920302082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":34,"alternative-id":["S0959804920302082"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported quality of life in patients with relapsed\/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}